echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ODSR: Comparison of colchicine in the treatment of acute gout.

    ODSR: Comparison of colchicine in the treatment of acute gout.

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Gout is a very common cause of inflammatory arthritis (pain, redness, heat, and swelling of the affected joints) .
    It is caused by the formation of urate crystals in or around the joints
    .


    Uric acid is a waste product normally produced in the body, usually excreted in urine


    The cause of inflammatory arthritis (pain, redness, heat, and swelling of the affected joints) is caused by the formation of urate crystals in or around the joints


    Search method: We have updated the search of CENTER, MEDLINE, EMBASE, ClinicalTrials.
    gov and the WHO ICTRP registry to August 28, 2020
    .


    We did not impose any date or language restrictions in the search


    Selection criteria: We considered published randomized controlled trials (RCT) and quasi-randomized controlled trials (quasi-RCT) to evaluate the efficacy of colchicine treatment and other treatments (placebo or other effective treatment methods) in acute gout, low The clinically relevant dose comparison of colchicine and placebo is the main comparison
    .


    The main results are pain, participants' overall assessment of treatment success (50% or more reduction in pain from baseline to 32 hours to 36 hours), reduction in inflammation, related joint function, serious adverse events, total adverse events, and adverse events due to And stop the drug


    Data collection and analysis: We used standard methodological procedures expected by Cochrane to collect data
    .

    Main results: In this latest review, we included four trials (803 random participants), including two new trials
    .


    A three-group trial compared high-dose colchicine (52 participants), low-dose colchicine (74 participants) and placebo (59 participants); one trial compared high-dose colchicine with Placebo was compared (43 participants); one trial compared low-dose colchicine with non-steroidal anti-inflammatory drugs (NSAIDs) (399 participants); and one trial compared low-dose colchicine Alkali was compared with Chuanhu anti-gout mixture (Chinese medicine compound) (176 participants)


    The average age of the participants ranged from 51.
    2 to 70 years, and the duration of the trial ranged from 48 hours to 12 weeks
    .


    Two trials have a low risk of bias, one trial may be susceptible to selection bias (random sequence generation), reporting bias, and other biases, while the other open-label trial has a higher risk of performance and detection bias


    For preliminary comparison, low quality evidence from one trial (103 participants, due to the inaccuracy and bias was demoted) showed that compared with placebo, low-dose colchicine may improve treatment outcome , risk of adverse events Little or no increase
    .


    The number of people who reported successful treatment (50% or more pain relief) within 32 to 36 hours, and the number of people who used low-dose colchicine (418/1000) was slightly higher than that of placebo (172/1000; risk ratio (RR) 2.


    Compared with placebo, low-dose colchicine may improve treatment outcomes .


    Compared with placebo, large doses of colchicine may improve symptoms, but increase the risk of harm


    More adverse events associated with higher doses

    Since few serious adverse events were reported in the trial, we cannot estimate the risk of serious adverse events in most comparisons
    .


    One trial (399 participants) reported three serious adverse reactions (one participant who received low-dose colchicine and two participants who received non-steroidal anti-inflammatory drugs) for reasons not related to the trial (low quality The evidence is downgraded due to bias and imprecision)
    .

    Table 1 Low-dose colchicine and placebo in the treatment of acute gout

    Table 1 Low-dose colchicine and placebo in the treatment of acute gout

    Table 2 High-dose colchicine and placebo in the treatment of acute gout

    Table 2 High-dose colchicine and placebo in the treatment of acute gout

    Table 3 Comparison of the effects of high-dose colchicine and low-dose colchicine on acute gout

    Table 3 Comparison of the effects of high-dose colchicine and low-dose colchicine on acute gout

    Table 4 Comparison of efficacy of low-dose colchicine and non-steroidal anti-inflammatory drugs

    Table 4 Comparison of efficacy of low-dose colchicine and non-steroidal anti-inflammatory drugs

    Conclusion: We found that compared with placebo, low-quality evidence suggests that low-dose colchicine may be an effective treatment for acute gout, and its benefits may be similar to non-steroidal anti-inflammatory drugs
    .
    We reduce the bias and imprecision of the evidence
    .
    Compared with placebo, high dose and low-dose colchicine can improve pain, low quality evidence suggests that compared with placebo, high dose (rather than low doses) colchicine may increase the number of adverse events, and low Quality evidence suggests that the number of adverse events may be similar in low-dose colchicine and NSAIDs
    .
    At present, there are no trials to report the effect of colchicine on people with comorbidities, or compare it with other commonly used treatment methods such as glucocorticoids
    .

    Low-dose colchicine may be an effective treatment for acute gout, and its benefits may be similar to non-steroidal anti-inflammatory drugs
    .
    Both high-dose and low-dose colchicine can improve pain.
    Compared with placebo, high-dose (rather than low-dose) colchicine may increase the number of adverse events.
    The number of adverse events may be in low-dose colchicine and NSAIDs Similar
    .

    Original source:

     McKenzie BJ, Wechalekar MD, Johnston RV,et al.
    Colchicine for acute gout.
    Ochrane Database Syst Rev 2021 Aug 26;8

    Colchicine for acute gout.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.